Product Overview
Generic Peptides labels this pack Duo-Blend CJC 5 mg / IPAM 5 mg, and the label is specific: one freeze-dried vial that carries 5 mg of CJC-1295 without DAC next to 5 mg of ipamorelin, 10 mg of peptide in total. The split is documented product data rather than a guess, which matters because every dilution figure below leans on it. The powder needs a solvent before use and the pack does not contain one.
The two halves knock on different doors. The CJC arm is the Mod GRF 1-29 sequence, a GHRH analogue that readies the pituitary, and ipamorelin is a selective secretagogue acting at the ghrelin receptor. Putting a releasing-hormone signal and a ghrelin signal in one syringe is the standard rationale for the pairing, and ipamorelin is the chosen partner because the literature describes it as leaving cortisol and prolactin alone. Each half also exists on its own in this section: CJC-1295 No DAC for the releasing-hormone side and Ipamorelin for the secretagogue side.
The missing drug affinity complex is what defines this vial. That anchor lets a peptide ride on albumin and spreads its activity across days, and the anchored molecule is a separate product, CJC-1295 DAC. Take the anchor away and the releasing-hormone arm lasts minutes instead of days, so a single daily injection cannot hold a signal steady. No approved form of this fixed blend exists and no published human trial of the mixture was located, so the page stays with dilution arithmetic and research conventions.
Fixed 1:1 Ratio and Dilution
With both arms documented at 5 mg, a mixed vial can be read as two numbers at once: total peptide in the syringe and the amount belonging to each half. The table gathers the vendor arithmetic and the amounts recorded for each half separately in research writing. It is a calibration aid, not a schedule.
| Item | Figure | Comment |
| Vial content | CJC-1295 no DAC 5 mg plus ipamorelin 5 mg | 10 mg of peptide in total, 1:1 by weight |
| Solvent | Bacteriostatic water | Run it down the glass wall and swirl; shaking damages peptides |
| Two millilitres added | 5 mg per ml | A 10 unit draw of 0.1 ml carries 500 mcg of mixture |
| Five millilitres added | 2 mg per ml | The same 10 unit draw now carries 200 mcg |
| Per arm, 5 mg per ml | 250 mcg each half | Half of the 500 mcg draw belongs to each peptide |
| Per arm, 2 mg per ml | 100 mcg each half | Half of the 200 mcg draw belongs to each peptide |
| CJC arm in research writing | 100-200 mcg per injection | DAC-free version only; the anchored molecule is a different pack |
| Ipamorelin arm in research writing | 200-300 mcg, 2-3 daily | Frequency dictated by the roughly 2 hour half-life |
| Timing | Empty stomach | About two hours after food; the pre-sleep dose is the usual placement |
| Block in vendor writing | 12-16 weeks plus 4 off | Borrowed from the ipamorelin protocol, not from blend data |
| Female | Not confirmed | The sources list no female amounts for the blend |
Two readings trip buyers up on a mixed vial: the total in the syringe and the share belonging to each half. At the stronger mix a 10 unit draw is 500 mcg split into 250 mcg per arm, and at the weaker mix the same draw is 200 mcg split into 100 mcg per arm. Neither reading is a recommendation; both are arithmetic that follows from the 1:1 label and the volume of water added.
The powder keeps best cold, dark and sealed at 2-8 C, and the mixed vial is a perishable item. Vendor convention for this peptide family quotes roughly 28-30 days at 2-8 C after reconstitution, and the sources give no exact figure for this particular pack, so a batch should be logged with its mixing date. Repeated freeze and thaw cycles of a dissolved peptide are not part of any convention found here.
Two-Receptor Protocols
The layouts below are research arrangements collected from vendor and community writing. No combination was tested against a control, and the fixed blend has no human data at all, so they are described as comparisons rather than routines.
Anyone comparing releasing-hormone options should put Sermorelin on the same shelf, since it is the older GHRH fragment with the longest clinical record. Users who want a longer window between shots belong with the anchored molecule rather than this vial, and users who want the finished hormone rather than a release signal start further down the pathway.
What to Expect
- Weeks 1-3: sleep and recovery first. Community and vendor accounts mention easier recovery and better sleep before anything else changes. These are reports, not measurements.
- Within the hour: the pharmacological event. Growth hormone leaves the pituitary shortly after a dose, but nothing is felt at that speed, so the mixture has to be evaluated across months rather than days.
- Two or three doses a day are the floor, not a preference. Halves of about 30 minutes and about 2 hours cannot be stretched into one morning shot.
- Meal timing changes the read-out. Injecting on a full stomach blunts the response, so the empty-stomach rule is part of the method.
- Months, not weeks, for composition. The 12-16 week block is the shortest window in which anything about body shape is discussed at all.
- Class complaints arrive as amounts climb. Puffiness, aching joints and aching muscles sit in the general tolerability notes for growth hormone peptides.
- Where the evidence stops. There is no peer-reviewed human dose for this mixture, and each arm is named in the banned class for tested athletes.
Side Effects and Management
Tolerability information for a fixed blend is thin, so most of what follows is class-level and is labelled that way.
Pulse Checks and No PCT
The blend raises endogenous growth hormone output and never touches the gonadal axis, so a SERM restart has nothing to fix on this page. What follows a block is measurement and a gap, not a drug.
Anyone who has been running suppressive compounds alongside a growth hormone peptide still needs the recovery protocol for those compounds, and that work belongs with the substances that caused the shutdown rather than with this vial. The blend itself simply ends: taper if the amount per injection is being stepped down, keep recording sleep, joints and appetite, and let the next block start from a clean baseline.
